Ignite Creation Date:
2024-05-06 @ 6:32 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05690828
Status:
RECRUITING
Last Update Posted:
2023-02-22
First Post:
2023-01-10
Brief Title:
Evaluation of Cognitive Management for Chemobrain in Patients Treated for Breast Cancer
Sponsor:
Institut Bergonié
Organization:
Institut Bergonié
Study Overview
Official Title:
Etude e-ONCOGITE Évaluation dUne Prise en Charge Cognitive adaptée au Chemobrain Chez Des Patientes traitées Pour un Cancer de Sein
Status:
RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
e-ONCOGITE
Brief Summary:
This project will investigate the efficacy of a cognitive remediation programme in patients treated for breast cancer patients will be randomized between no intervention and intervention programme Efficay will be assessed in term of improved quality of life
Detailed Description:
Medical progress in the treatment of cancer has prolonged patients life expectancy This improvement has led researchers to become concerned about the long-term negative effects of cancer treatments on quality-of-life In particular previous studies have identified complaints that have been submitted concerning the cognitive status of patients treated with chemotherapy Berglund et coll 1991 All of these cognitive changes are collectively grouped under the term chemobrain
The consequences of treatments remain however underestimated as the priority when diagnosing cancer remains the patients short- to medium-term survival yet quality-of-life contributes to the long-term survival of patients Kramer 2000
In addition to medical treatments psychosocial care adapted to the specific needs of subjects is thus important for improving their quality-of-life and helping them return to work Even if initiatives have multiplied over the past few decades in the psychosocial management of these subjects eg supportive care that related to cognitive disorders in subjects having survived cancer remains a little documented field Cognitive deficiency in cancer survivors is said to be moderate Razaq et coll 2017 which makes survivors ideal candidates for cognitive rehabilitation
The consequences of treatments remain however underestimated as the priority when diagnosing cancer remains the patients short- to medium-term survival yet quality-of-life contributes to the long-term survival of patients Kramer 2000
In addition to medical treatments psychosocial care adapted to the specific needs of subjects is thus important for improving their quality-of-life and helping them return to work Even if initiatives have multiplied over the past few decades in the psychosocial management of these subjects eg supportive care that related to cognitive disorders in subjects having survived cancer remains a little documented field Cognitive deficiency in cancer survivors is said to be moderate Razaq et coll 2017 which makes survivors ideal candidates for cognitive rehabilitation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None